Retrophin (RTRX) Downgraded by BidaskClub

BidaskClub lowered shares of Retrophin (NASDAQ:RTRX) from a buy rating to a hold rating in a research note issued to investors on Saturday.

A number of other brokerages also recently commented on RTRX. BMO Capital Markets restated a buy rating and set a $44.00 target price on shares of Retrophin in a report on Friday, October 6th. Zacks Investment Research upgraded Retrophin from a strong sell rating to a hold rating in a report on Thursday, January 4th. Finally, ValuEngine downgraded Retrophin from a hold rating to a sell rating in a report on Saturday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $44.00.

Shares of Retrophin (RTRX) traded down $1.07 during trading on Friday, hitting $22.79. The company had a trading volume of 224,930 shares, compared to its average volume of 203,216. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88. The company has a market capitalization of $874.80, a P/E ratio of -17.27 and a beta of 1.26. Retrophin has a one year low of $15.55 and a one year high of $26.44.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.21). The business had revenue of $40.34 million for the quarter, compared to the consensus estimate of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. Retrophin’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.09) EPS. equities analysts predict that Retrophin will post -1.24 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its holdings in shares of Retrophin by 4.3% during the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 355 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Retrophin during the third quarter valued at approximately $203,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Retrophin during the third quarter valued at approximately $212,000. Campbell & CO Investment Adviser LLC bought a new position in Retrophin in the third quarter worth $249,000. Finally, GSA Capital Partners LLP bought a new position in Retrophin in the second quarter worth $279,000.

ILLEGAL ACTIVITY WARNING: This piece was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply